Enlivex Ltd.

Enlivex Ltd. is a clinical-stage macrophage reprogramming immunotherapy company based in Ness Ziona, Israel, founded in 2005. The company's core mission is to develop innovative cell therapies, primarily Allocetra, designed to reprogram macrophages into their homeostatic state to address various inflammatory diseases and rebalance immune hyper-responses. Beyond its therapeutic pipeline, Enlivex has adopted a unique dual strategy, positioning itself as a "quality longevity company powered by a Prediction Markets Treasury," integrating digital asset management into its financial model.

Enlivex's primary product candidate, Allocetra, is an off-the-shelf cell therapy currently in clinical development for several indications. These include organ dysfunction and failure caused by sepsis (Phase II), and various forms of osteoarthritis, such as moderate knee osteoarthritis (Phase I/II, Phase IIb), end-stage knee osteoarthritis (Phase I/II), Basal thumb osteoarthritis (Phase I/II), and Psoriatic arthritis (Phase I/II). The company aims to restore mobility, independence, and functional life, particularly in aging populations, by targeting unmet medical needs in inflammatory and autoimmune diseases.

In a significant corporate development, the company formally changed its name from Enlivex Therapeutics Ltd. to Enlivex Ltd. in February 2026. Recent notable activities include the appointment of former Italian Prime Minister Matteo Renzi to its board of directors in November 2025. Enlivex reported a net income of $1.23 billion for the full year 2025, largely driven by the appreciation of its treasury and treasury-related derivative assets, specifically RAIN tokens, which are part of its prediction markets treasury strategy. The company also received FDA clearance and a second regulatory approval for a Phase IIb clinical trial of Allocetra in age-related primary moderate-to-severe knee osteoarthritis, with top-line data anticipated in 2027. As of April 2026, its RAIN token holdings exceeded 78 billion tokens, valued at $567 million, and the token was listed on the HTX cryptocurrency exchange. Oren Hershkovitz serves as the CEO, with Shai Novik as the Executive Chairman.